USNA: Hiya subscriber growth accelerated, but lower Core and Rise sales drove a 3.6% Q3 revenue decline

What happened

USANA Health Sciences reported that third-quarter sales fell 3.6% year over year. Hiya subscribers increased 18% sequentially, but lower sales in Core Nutritional and Rise offset that growth. The supplied summary says sales guidance is approaching $900 million and adjusted EBITDA, a measure of earnings, is $77 million.

Confirmed

Global impact / market context

The decline shows that subscriber growth in Hiya has not yet offset weaker sales in USANA’s Core Nutritional and Rise businesses. If those sales remain low, they could weigh on total revenue even as Hiya adds subscribers; guidance and adjusted EBITDA provide additional measures of the company’s outlook and earnings.

Analyst inference

The supplied figures point to mixed business performance: Hiya subscribers rose, while overall quarterly sales fell. For investors, the key distinction is whether subscriber gains translate into enough revenue to counter weakness in the other divisions; the summary gives no division-level sales figures or explanation for the declines.

Analyst inference

What to watch

1. Watch whether future reports show Hiya subscriber growth continuing and bringing in enough sales to help offset lower sales in Core Nutritional and Rise. Analyst inference
2. Compare reported sales with guidance approaching $900 million, and check whether adjusted EBITDA, a measure of earnings, is near $77 million. Analyst inference
3. Look for further details on Core Nutritional and Rise sales, since the supplied summary does not explain what drove their declines or how they may affect revenue. Analyst inference

Evidence

• Original source link unavailable